A Comparison of Treatments and Outcomes for Medullary versus Nonmedullary Colon Cancer: A Single Institutional Experience Showing a Worse Prognosis for Stage 3 Disease.
Publication/Presentation Date
1-1-2020
Abstract
BACKGROUND: Prior studies have shown a better prognosis with medullary colon cancer (MCC) compared to nonmedullary colon carcinomas (NMC); however, data are inconsistent and lacking the evaluation of treatments received. As we did not see similar survival outcomes, we aimed to retrospectively examine survival and receipt of treatment differences between MCC and NMC within the Geisinger Health System.
METHODS: The Cancer Registry was retrospectively reviewed for MCC and NMC from 2006 to 2017. Demographics and treatments were compared using
RESULTS: 33 MCC and 1775 NMC patients were identified and 31 (93.9%) MCC and 1433 (87.0%) NMC underwent resection. MCC were older (
CONCLUSION: Multiple previous studies showed a better prognosis for MCC compared to PD/UD NMC. We, however, found stage 3 patients had a worse prognosis which may be secondary to higher comorbidities, increased stage, and higher rate of UD.
Volume
2020
First Page
5783729
Last Page
5783729
ISSN
2356-7759
Published In/Presented At
Gupta, A., Protyniak, B., Dove, J., Chu, K., Erchinger, T., Bannon, J., & Oxenberg, J. (2020). A Comparison of Treatments and Outcomes for Medullary versus Nonmedullary Colon Cancer: A Single Institutional Experience Showing a Worse Prognosis for Stage 3 Disease. Surgery research and practice, 2020, 5783729. https://doi.org/10.1155/2020/5783729
Disciplines
Medicine and Health Sciences
PubMedID
32280741
Department(s)
Department of Surgery
Document Type
Article